Search - tctmd.com

Displaying 841 - 860 of 1866

Sort: Relevancy | Date

Presentation

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

April 17, 2018

News Daily News

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Michael O'Riordan

April 16, 2018

News Daily News

Abciximab in ‘Short Supply’ Worldwide

Shelley Wood

April 13, 2018

Presentation Fellows 2018

ACS Pharmacology for the Interventionalist

Presenter: Duane S. Pinto, Gregg W. Stone

April 13, 2018

News Daily News

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Michael O'Riordan

April 05, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

Podcast TCTMD Talking Points

Robotic PCI in Practice and Training

April 04, 2018

News Daily News

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

Shelley Wood

March 29, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Podcast TCTMD Talking Points

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

March 21, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Presentation ACC 2018

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

Presenter: Hyeon-Cheol Gwon

March 12, 2018

Presentation ACC 2018

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

Presenter: Diego Ardissino

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticouagulants

Presentation ACC 2018

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

Presenter: Steve Deitelzweig

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

Advertisement

Preangioplasty iFR Pullback Predicts Hemodynamic Outcome in CAD: iFR GRADIENT Registry

Women With MI Less Likely Than Men to Fill Prescription for High-Intensity Statins

Abciximab in ‘Short Supply’ Worldwide

ACS Pharmacology for the Interventionalist

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Robotic PCI in Practice and Training

Time for Guidelines to Recommend ARBs Over ACE Inhibitors?

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

6-Month versus 12-Month or Longer Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome (SMART-DATE)

The PHARMCLO Study: A Prospective, Randomised, Multicentre Study of a Pharmacogenomic Approach to the Selection of Antiplatelet Therapy in Acute Coronary Syndromes

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Comparison of Effectiveness, Safety, and The Net Clinical Outcome Between Different Direct Oral Anticoagulants

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content